**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65674

**Manuscript Type:** EDITORIAL

**Importance of *BRCA* mutation for the current treatment of pancreatic cancer beyond maintenance**

Martínez-Galán J *et al*. Importance of *BRCA* in PC

Joaquina Martínez-Galán, Isabel Rodriguez, Octavio Caba

**Joaquina Martínez-Galán, Isabel Rodriguez,** Department of Medical Oncology, Virgen de las Nieves University Hospital, Granada 18014, Spain

**Octavio Caba,** Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Granada 18016, Spain

**Author contributions:** Martinez-Galan J designed the overall concept and outline of the manuscript; Caba O contributed to the discussion, and carried out the design of the manuscript; Martinez-Galan J and Rodriguez I contributed to the writing and editing of the manuscript and review of the literature.

**Supported by** Junta de Andalucía, No. PC-0498-2017 and No. PC-0549-2017.

**Corresponding author: Octavio Caba, PhD, Professor,** Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, Avenida del Conocimiento s/n, Granada 18016, Spain. ocaba@ugr.es

**Received:** March 16, 2021

**Revised:** May 10, 2021

**Accepted:** September 3, 2021

**Published online:**

**Abstract**

In this editorial, we comment on pancreatic cancer (PC), one of the most aggressive and lethal cancers. Only minimal improvements in survival rates have been achieved over recent years. Available chemotherapeutic regimens have little impact, and surgical resection remains the only reliable curative approach. We address current treatment options for these patients, focusing on the usefulness of *breast cancer (BRCA)* gene mutation as a prognostic biomarker and predictor of response to chemotherapy. Superior survival outcomes have been reported in patients with PC and mutant *BRCA* gene treated with first-line platinum-based chemotherapy. Therefore, it appears appropriate to include *BRCA* gene status among clinical criteria used to select the chemotherapy regimen. In addition, maintenance treatment with poly(ADP-ribose) polymerase inhibitors has been found to improve progression-free survival in patients with PC and mutated *BRCA* whose disease does not progress after first-line platinum-based chemotherapy. This combination has therefore been proposed as the optimal treatment regimen for these patients.

**Key Words:** Pancreatic cancer; Treatment; *BRCA*; Mutation; Poly(ADP-ribose) polymerase inhibitor; Maintenance

Martínez-Galán J, Rodriguez I, Caba O. Importance of *BRCA* mutation for the current treatment of pancreatic cancer beyond maintenance. *World J Gastroenterol* 2021; In press

**Core Tip:** Pancreatic cancer remains one of the most lethal malignant neoplasms, and available treatments have several limitations. Genetic studies are not currently recommended to support treatment selection. However, *breast cancer (BRCA)* gene mutationhas been associated with superior survival outcomes in patients treated with platinum-based chemotherapy. Hence, it appears appropriate to consider the *BRCA* gene status of patients with this cancer among clinical criteria for the selection of first-line chemotherapy regimen.

**INTRODUCTION**

Pancreatic cancer (PC) continues to be one of the most lethal malignant neoplasms, with a 5-year survival rate of only 5%[1]. It currently represents the third cause of cancer-related mortality and is expected to be the second by 2030[2]. Surgery is considered the sole potentially curative treatment; however, only 20% of patients diagnosed with PC are candidates for surgery at the time of diagnosis, and surgical resection is frequently followed by recurrence and therapeutic resistance[3].

There have been only limited advances in PC treatment over the past few decades. However, progress in basic research has recently generated increased molecular information on PC, improving knowledge of its biology and helping to explain the poor effectiveness of current therapies and the therapeutic resistance observed[4]. For instance, *KRAS*[5], *breast cancer* (*BRCA)*[6], and *ataxia-telangiectasia mutated*[7] genes play a major role in the prognosis and response to treatment of patients with advanced PC. Hence, the identification of patients with mutations in these genes can support the design of individualized therapies that may improve survival outcomes.

In this article, we evaluate the usefulness of *BRCA* gene mutation as a prognostic and predictive biomarker of the response to chemotherapy in PC patients, beyond their maintenance treatment.

**CURRENT ADVANCED PC TREATMENT**

Two first-line chemotherapy options are currently available for advanced PC, FOLFIRINOX and gemcitabine+nab-paclitaxel (GEM+Nab-P)[8]. These have both demonstrated superior overall survival (OS), progression-free survival (PFS), and response rates (RRs) compared to patients receiving monotherapy with gemcitabine. Specifically, the PRODIGE4/ACCORD11 study reported improved OS (11.1 *vs* 6.8 mo, respectively), PFS (6.4 *vs* 3.3 mo), and RR (31.6% *vs* 9.4%) in the FOLFIRINOX *vs* gemcitabine arm[9]. The MPACT study also reported improved OS (8.7 *vs* 6.6 mo), PFS (5.5 *vs* 3.7 mo), and RR (23% *vs* 7%) with GEM+Nab-P *vs* gemcitabine alone[10]. The higher percentage improvements obtained in the PRODIGE4/ACCORD11 study may be explained by the more favorable prognosis of the participants, who were less representative of the real-life clinical setting compared to those in the MPACT study. Specifically, the functional Eastern Cooperative Oncology Group score was 0 in 37% of PRODIGE4/ACCORD11 study participants *vs* 16% of MPACT study participants, the pancreatic head was tumor site in < 40% of the former *vs* 44% of the latter (60%-65% in clinical practice), the mean number of metastatic sites was two in the former *vs* three in the latter, the carbohydrate antigen 19-9 marker was elevated in 42% of the former *vs* 52% of the latter, and no patient over the age of 76 years participated in the former study. It should be noted that the higher survival and RRs in the PRODIGE4/ACCORD11 study were accompanied by a significant increase in hematologic and non-hematologic toxicity. This explains why FOLFIRINOX is frequently administered at a reduced dose or in modified form in the clinical setting. Finally, no randomized trials have been undertaken to compare these options, hampering evaluation of the optimal first-line treatment of PC. The only published studies have a retrospective or non-randomized prospective design, and the results have been contradictory[11-13]. Consequently, the choice of chemotherapy regimen largely depends on clinical variables, such as the performance status and previous comorbidities of patients[14,15].

There are currently no recommendations for genetic studies to support the selection of PC treatments. One promising approach is the identification of mutations in genes involved in response mechanisms to DNA damage, such as *BRCA,* whose mutationhas been associated with superior OS outcomes in PC patients treated with platinum-based chemotherapy[16]. This evidence is based on multiple *in vitro* studies and is supported by the longer OS observed in patients with advanced PC treated with platinum-based regimens who were *BRCA* mutation carriers than in those who were not (14 mo *vs* 5 mo; hazard ratio [HR] = 0.58; *P* = 0.08); however, this clinical trial was retrospective and only included 12 patients[17].

**ROLE OF poly(ADP-ribose) polymerase AND ITS IMPORTANCE IN MUTATED *BRCA***

Mutations in the genetic code must be detected and repaired to preserve genome integrity, avoiding the uncontrolled proliferation of healthy cells and possible development of cancer[18]. One DNA repair pathway detects single-strand DNA breaks. If defective, another pathway is involved in the detection of double-strand DNA breaks followed by their homologous recombination repair (HRR), using sister chromatids to restore the original DNA sequence in a high-fidelity mechanism[19]. Nuclear enzyme poly(ADP-ribose) polymerase (PARP) is responsible for detecting DNA damage and facilitating its repair. Specifically, PARP1, the main member of the PARP family, binds to and repairs both single- and double-strand DNA breaks[20]. Conversely, PARP1 inhibition results in persistent single-strand DNA breaks that lead to replication bifurcations and double-strand DNA breaks[21].

About 7% of PC patients possess *BRCA* mutations[22]. In these patients, the inhibition of PARP and resulting loss by the tumor of functional DNA repair pathways can synergically interact and produce the specific death of tumor cells. Studies in patients with ovarian, prostate, or breast cancer found that PARP inhibition enhances the activity of cytotoxic DNA agents including alkylating agents, topoisomerase inhibitors, and radiotherapeutic agents[23]. Hence, it appears plausible to assume distinct biological behaviors and responses to therapy in patients with advanced PC who have *BRCA* mutations, especially germline mutations. This has implications for the treatment selection and suggests that *BRCA* mutations may be a useful biomarker to predict the response to first-line treatment with platinum.

**PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PC AND MUTATED *BRCA* GENE**

Tumors with *BRCA* mutations are phenotypically characterized by their susceptibility to platinum-based chemotherapy, as noted above. *BRCA*-deficient cells accumulate double-strand DNA breaks, generating genomic instability and a greater predisposition to malignant transformation and progression. This is because the loss of HRR and PARP1 pathways leads to so-called synthetic lethality during DNA replication[24].

Patients with ovarian cancer who had mutated *BRCA*, either of somatic or germline origin, respond better to platinum-based chemotherapy regimens, with a superior prognosis and survival rate compared to those without this mutation[25]. In a study of 549 patients with metastatic PC, 78% of whom had at least one family member with a history of cancer, a median OS (mOS) of 8.1 mo (95% confidence interval [CI]: 7.5-9.0) was achieved by platinum-based chemotherapy, and 31% remained alive at 1 year. The mOS was higher in the patients with a family history of breast or ovarian cancer (8.5 mo; HR = 0.76; *P* = 0.042) and even higher in those with a family history of pancreatic and breast or ovarian cancer (14.8 mo; HR = 0. 43; *P* = 0.0003)[17]. According to these findings, a substantial subpopulation of patients with PC could benefit from platinum-based regimens. However, the underlying molecular mechanisms have not yet been elucidated, and further research is warranted in patients with *BRCA* mutant/deficient profiles. Other studies of PC patients receiving platinum-based chemotherapy have described a longer OS in those with a family history of breast, ovarian, or PC than in those with no family history of these cancers[26].

Cells with mutated *BRCA* are more susceptible to platinum and anthracyclines, which are selectively lethal in cells with HRR defects[27]. In a retrospective study of 36 PC patients treated with FOLFIRINOX, multivariate analyses confirmed a significantly longer mOS in patients with *vs* without homologous repair gene mutations (odds ratio [OR] = 1.47; 95%CI: 1.04-2.06; *P* = 0.04)[17].In a study by Lowery *et al*[28] of 15 patients with advanced PC and germline *BRCA* mutation (*BRCA1* in 4 [27%] and *BRCA2* in 11 [73%]), 6 received platinum chemotherapy as first-line treatment, and 5 of these had a radiological partial response according to RECIST criteria, while the remaining patient had a complete response to the infusion of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan[28]. A study by Golan *et al*[26] of 71 patients with PC and a mutation in *BRCA1* (*n* = 21), *BRCA2* (*n* = 49), or both (*n* = 1) reported a longer mOS in patients treated with platinum than in those receiving other agents (22 *vs* 4.4 mo, respectively); the authors concluded that outcomes are more favorable in patients with PC who have *BRCA1* or *BRCA2* mutations than in those who do not[26].

**USEFULNESS OF iPARP IN PC WITH MUTATED *BRCA***

In the highly influential POLO study[29], 154 patients with PC and germline *BRCA* mutation who showed no disease progression after at least 16 wk with FOLFIRINOX were randomly assigned to a group receiving maintenance therapy with olaparib, a PARP inhibitor (iPARP), or to a group receiving no maintenance treatment. Patients in the olaparib group showed a statistically significant improvement in PFS (7.4 mo *vs* 3.8 mo; HR = 0.53; 95%CI: 0.35-0.82), and 22% of them remained progression-free at 2 years compared to 9.6% in the untreated group, although there was no between-group difference in OS (18.9 *vs* 18.1 mo, respectively). Accordingly, the United States Food and Drug Administration approved olaparib as maintenance therapy for patients with advanced PC and germline *BRCA* mutation who show no disease progression after at least 16 wk of first-line treatment with platinum-based chemotherapy. In this regard, it has been reported that the iPARP-associated response does not depend on the germline or somatic origin of the *BRCA* mutation. Thus, one meta-analysis[22] describes eight studies that reported a response to PARPi in 24/43 (55.8%) patients with somatic *BRCA* mutation *vs* 69/157 (43.9%) patients with germline *BCRA* mutation, a non-significant difference (*P* = 0.399). In addition, five studies in the meta-analysis found no difference in PFS between patients with somatic *vs* germline *BCRA* mutations. The authors concluded that the response to iPARP therapy is similar between these types of patient.

Platinum-based chemotherapy has been combined with the administration of iPARP. An open-label, randomized, multicenter phase II trial was conducted on the efficacy of cisplatin plus gemcitabine with *vs* without veliparib in 50 patients with PC and germline-mutated *BRCA*. The RR was 74.1% for cisplatin plus gemcitabine with veliparib *vs* 65.2% for cisplatin plus gemcitabine alone (*P* = 0.55), obtaining a disease control rate of 100% with the former regimen *vs* 78.3% with the latter (*P* = 0.02). According to the authors, cisplatin plus gemcitabine is effective in advanced germline-mutated *BRCA* PC, and the addition of veliparib offers no improvement in therapeutic response[30-32]. These results support the selection of platinum-based chemotherapy as first-line treatment for patients with PC and germline *BRCA* mutation.

Various clinical trials are currently exploring the combination of iPARP with different chemotherapy and immunotherapy regimens (Table 1). It has been proposed that PARP inhibition induces tumor immunogenicity by increasing the tumor antigen load and the expression of programmed death-ligand 1 in tumor tissue, thereby increasing the susceptibility of patients with *BRCA* mutations to immunotherapy, as already demonstrated in breast cancer[33], small cell lung cancer[34], and ovarian cancer[35].

In summary, current studies suggest that *BRCA* mutation status may be a useful prognostic and predictive biomarker of the response to platinum in patients with PC, identifying those who may benefit from platinum-based chemotherapy as standard first-line treatment.

**CLINICAL IMPLICATIONS**

PC is associated with a poor prognosis and high resistance to chemotherapy. Fewcytotoxic agents have demonstrated activity against this tumor, including platinum-based (FOLFIRINOX) and gemcitabine-based (GEM+Nab-P) regimens, and they deliver very modest benefits to the patient. There has been no comparative study of these agents to determine which is more appropriate as a first-line treatment, and this decision relies on the clinical characteristics and comorbidities of the patients. Two important issues must still be resolved: the best regimen for the personalization and optimization of first-line chemotherapy in patients with PC; and the ideal sequencing of chemotherapy lines, taking into account the accumulated toxicity and the molecular profile of the cancer.

As noted above, the *BRCA* gene encodes proteins essential for repairing double-strand DNA damage *via* the HRR pathway, and its mutation has been found to predict the response to first-line chemotherapy with platinum plus iPARP in patients with PC[26]. Thus, patients with advanced PC and germline *BRCA* mutation lived significantly longer when treated with platinum *vs* other cytotoxic agents[17]. In addition, maintenance treatment with iPARP has been found to improve the PFS of patients with PC and mutated *BRCA* whose disease does not progress after first-line platinum-based chemotherapy. Taken together, these findings support the selection of platinum-based regimens as first-line treatment of patients with PC and germline *BRCA* mutation[30-32].

Given the lack of evidence on the optimal treatment of patients with PC, it appears appropriate to consider the presence/absence of *BRCA* mutation among clinical criteria for the selection of first-line chemotherapy regimen.

**CONCLUSION**

An appreciable number of patients with PC have a mutated *BRCA* gene, and the ongoing development of drugs that target DNA repair pathways may offer relevant therapeutic benefits to this little-studied but clinically important sub-population. This defect in DNA repair pathways has the potential to improve outcomes in patients undergoing platinum-based chemotherapy, assisting individualized selection of the optimal first-line regimen.

**ACKNOWLEDGEMENTS**

The authors are grateful to Richard Davies for assistance with the English version.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]

2 **Rahib L**, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155]

3 **Martin-Perez E**, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. *Clin Transl Oncol* 2020; **22**: 1963-1975 [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6]

4 **Zeng S**, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in Pancreatic Cancer. *Int J Mol Sci* 2019; **20** [PMID: 31514451 DOI: 10.3390/ijms20184504]

5 **Buscail L**, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 153-168 [PMID: 32005945 DOI: 10.1038/s41575-019-0245-4]

6 **Luo G**, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. *Expert Rev Anticancer Ther* 2015; **15**: 1223-1231 [PMID: 26402249 DOI: 10.1586/14737140.2015.1086271]

7 **Armstrong SA**, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. *Mol Cancer Ther* 2019; **18**: 1899-1908 [PMID: 31676541 DOI: 10.1158/1535-7163.MCT-19-0208]

8 **Neoptolemos JP**, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 333-348 [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x]

9 **Conroy T**, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX *vs* gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]

10 **Von Hoff DD**, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; **369**: 1691-1703 [PMID: 24131140 DOI: 10.1056/NEJMoa1304369]

11 **Kim S**, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine *vs* FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. *Adv Ther* 2018; **35**: 1564-1577 [PMID: 30209750 DOI: 10.1007/s12325-018-0784-z]

12 **Tempero MA**, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. *J Natl Compr Canc Netw* 2019; **17**: 202-210 [PMID: 30865919 DOI: 10.6004/jnccn.2019.0014]

13 **Williet N**, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J. Folfirinox *versus* gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. *Therap Adv Gastroenterol* 2019; **12**: 1756284819878660 [PMID: 31598136 DOI: 10.1177/1756284819878660]

14 **Pavel M**, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2020; **31**: 844-860 [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304]

15 **Hidalgo M**, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. *Clin Transl Oncol* 2017; **19**: 667-681 [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x]

16 **Mylavarapu S**, Das A, Roy M. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. *Front Oncol* 2018; **8**: 16 [PMID: 29459887 DOI: 10.3389/fonc.2018.00016]

17 **Sehdev A**, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. *Clin Cancer Res* 2018; **24**: 6204-6211 [PMID: 30131383 DOI: 10.1158/1078-0432.CCR-18-1472]

18 **Lord CJ**, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. *Science* 2017; **355**: 1152-1158 [PMID: 28302823 DOI: 10.1126/science.aam7344]

19 **Hoeijmakers JH**. Genome maintenance mechanisms for preventing cancer. *Nature* 2001; **411**: 366-374 [PMID: 11357144 DOI: 10.1038/35077232]

20 **Alemasova EE**, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. *Nucleic Acids Res* 2019; **47**: 3811-3827 [PMID: 30799503 DOI: 10.1093/nar/gkz120]

21 **Mateo J**, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. *Ann Oncol* 2019; **30**: 1437-1447 [PMID: 31218365 DOI: 10.1093/annonc/mdz192]

22 **Mohyuddin GR**, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic *vs* Germline BRCA mutations: a Meta-analysis and systematic review. *BMC Cancer* 2020; **20**: 507 [PMID: 32493233 DOI: 10.1186/s12885-020-06948-5]

23 **Kamel D**, Gray C, Walia JS, Kumar V. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. *Curr Drug Targets* 2018; **19**: 21-37 [PMID: 28699513 DOI: 10.2174/1389450118666170711151518]

24 **Hu Y**, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. *Cancer Sci* 2020; **111**: 3111-3121 [PMID: 32639661 DOI: 10.1111/cas.14565]

25 **Ray-Coquard I**, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019; **381**: 2416-2428 [PMID: 31851799 DOI: 10.1056/NEJMoa1911361]

26 **Golan T**, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. *Br J Cancer* 2014; **111**: 1132-1138 [PMID: 25072261 DOI: 10.1038/bjc.2014.418]

27 **Tung NM**, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. *Br J Cancer* 2018; **119**: 141-152 [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5]

28 **Lowery MA**, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. *Oncologist* 2011; **16**: 1397-1402 [PMID: 21934105 DOI: 10.1634/theoncologist.2011-0185]

29 **Golan T**, Locker GY, Kindler HL. Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. *N Engl J Med* 2019; **381**: 1492-1493 [PMID: 31597029 DOI: 10.1056/NEJMc1911185]

30 **O'Reilly EM**, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline *BRCA/PALB2* Mutation. *J Clin Oncol* 2020; **38**: 1378-1388 [PMID: 31976786 DOI: 10.1200/JCO.19.02931]

31 **Fazio N**. Cisplatin Plus Gemcitabine as Standard of Care for Germline *BRCA/PALB2*-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast? *J Clin Oncol* 2020; **38**: 2466-2467 [PMID: 32407212 DOI: 10.1200/JCO.20.00419]

32 **O'Reilly EM**, Park W, Kelsen DP. Reply to N. Fazio. *J Clin Oncol* 2020; **38**: 2467-2468 [PMID: 32407214 DOI: 10.1200/JCO.20.00833]

33 **Jiao S**, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. *Clin Cancer Res* 2017; **23**: 3711-3720 [PMID: 28167507 DOI: 10.1158/1078-0432.CCR-16-3215]

34 **Sen T**, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. *Cancer Discov* 2019; **9**: 646-661 [PMID: 30777870 DOI: 10.1158/2159-8290.CD-18-1020]

35 **Rocconi RP**, Monk BJ, Walter A, Herzog TJ, Galanis E, Manning L, Bognar E, Wallraven G, Stanbery L, Aaron P, Senzer N, Coleman RL, Nemunaitis J. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. *Gynecol Oncol* 2021; **161**: 676-680 [PMID: 33715892 DOI: 10.1016/j.ygyno.2021.03.009]

**Footnotes**

**Conflict-of-interest statement:** Joaquina Martinez-Galan, Isabel Rodriguez, and Octavio Caba have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 16, 2021

**First decision:** May 1, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Spain

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Nemunaitis J, Shimada S, Wang WQ **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:**

**Table 1 Clinical trials on the combination of poly(ADP-ribose) polymerase inhibitor with chemotherapy and immunotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Identifier** | **Phase** | **iPARP** | **Title** | **Status** |
| NCT04548752 | II | Olaparib | Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab *vs* Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations | Recruiting |
| NCT02890355 | II | [Veliparib](https://www.clinicaltrials.gov/ct2/show/NCT02890355?cond=Pancreas+Cancer%2C+Metastatic&intr=Veliparib&age=1&phase=12&draw=2&rank=2) | **Randomized Phase II Study of 2nd Line FOLFIRI *vs* Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer** | Active, not recruiting |
| NCT01585805 | II | Veliparib | **A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)** | Active, not recruiting |
| NCT01489865 | I/II | ABT-888 | **A Phase I/II Study of ABT-888 in combination with 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients with Metastatic Pancreatic Cancer** | Active, not recruiting |
| NCT03404960 | I/II | Niraparib + Nivolumab  Niraparib + Ipilimumab | **PARPVAX: A Phase 1b/2, Open Label Study of Niraparib Plus either Ipilimumab or Nivolumab in Patients with Advanced Pancreatic Cancer whose disease has not progressed on Platinum-based Therapy** | Recruiting |
| NCT03553004 | II | Niraparib | **Niraparib in Metastatic Pancreatic Cancer after previous Chemotherapy (NIRA-PANC)** | Recruiting |

iPARP: Poly(ADP-ribose) polymerase inhibitor.